Abstract
Objective: To assess the prognostic value of I-123 metaiodobenzylguanidine, (MIBG) scintigraphy findings, and establish the most appropriate method for calculating myocardial MIBG activity in patients with left ventricular dysfunction due to cardiomyopathy (CM).Methods: Predictors of cardiac death related to progressive heart failure (HF) were examined in 150 patients with CM (80 patients with idiopathic CM and 70 patients with ischemic CM). All patients underwent MIBG scintigraphy at rest and other hemodynamic studies when their clinical status was stable. MIBG scintigrams were obtained 15 minutes and 4 hours after the injection of the isotope. The parameters for quantification of myocardial MIBG activity were heart/mediastinal activity ratio (H/M) and myocardial washout rate (WR). The WR was calculated with and without background (BG) correction.Results: The WR showed better, correlation with plasma norepinephrine and left ventricular ejection fraction after BG correction. During a mean follow-up period of 33±9 (7 to 54) months, 12 patients died due to HF; 7 patients due to progressive HF and 5 patients due to sudden cardiac death. Cox regression analysis indicated, the H/M and the WR with and without BG correction, were significant predictors of cardiac death (Wald chi-squared value: H/M [15 min]=9.7, H/M [4 hr]=19.5, WR with BG correction=29.9, WR without BG correction=12.6). WR prognostic value was better after BG correction, and a high WR with BG correction was the only independent predictor of cardiac death (relative risk [RR]=1.174, p<0.0001).Conclusions: Accelerated WR is a powerful predictor of the patient's prognosis and BG correction is essential for calculating WR.
Similar content being viewed by others
References
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS et al. Plasma norepinephrine as a guide to prognosis in patients with Heart Failure.N Engl J Med 1984; 311: 819–823.
Wieland DM, Wu JI, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzlguanidine.J Nucl Med 1980; 21: 349–353.
Glowniak JV, Frederick ET, Lori LG, Robert TP, Manuel CL-S, William RW. Iodine-123 Metaiodobenzylguanidine Imaging of the Heart in Idiopathic Congestive Cardiomyopathy and Cardiac Transplants.J Nucl Med 1989; 30: 1182–1191.
Glowniac JV. Cardiac Studies with Metaiodobenzylguanidine: A Critique of Methods and Interpretation of Results.J Nucl Med 1995; 36: 2133–2137.
Imamura Y, Ando H, Mitsuoka W, Egasira S, Masaki H, Fukuyama T. I-123 Metaiodobenzylguanidine Imagings Reflect the Intense Myocardial Adrenergic Nervous Activity of Congestive Heart Failure Independent from the Underlying Cause.J Am Coll Cardiol 1995; 26: 1594–1599.
Imamura Y, Ando H, Fukuyama T. Myocardial Adrenergic Nervous Activity Is Intensified in Patients with Heart Failure without Left Ventricular Volume or Pressure Overload.J Am Coll Cardiol 1996; 28: 371–375.
Merlet P, Valette H, Dubois-Rande J-L, Moyse D, Duboc D, Dove P, et al. Prognostic Value of Cardiac Metaiodobenzylguanidine Imaging in Patients with HF.J Nucl Med 1992; 33: 471–477.
Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of Underlying Etiology and Cardiac Sympathetic Innervation to Identify Patients at High Risk of Cardiac Death.J Nucl Med 2001; 42: 1757–1767.
Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K; on behalf of the Ehime MIBG Heart Failure Study Investigators. Prognostic Value of I-123 Metaiodobenzylguanidine Imaging and Cardiac Natriuretic Peptide Levels in Patients with Left Ventricular Dysfunction Resulting from Cardiomyopathy.Jpn Circ J 2001; 65: 155–160.
Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande J-L, Duval AM, et al. Prognostic Value of MIBG Imaging in Idiopathic Dilated Cardiomyopathy.J Nucl Med 1999; 40: 917–923.
Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE Inhibition Reduces Cardiac Iodine-123-MIBG Release in Heart Failure.J Nucl Med 1997; 38: 1085–1089.
Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R, et al. Cardiac Sympathetic Activity Estimated by123I-MIBG Myocardial Imaging in Patients with Dilated Cardiomyopathy after β-blocker or Angiotensin-Converting Enzyme Inhibitor Therapy.J Nucl Med 1999; 40: 217–223.
Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac Metaiodobenzylguanidine Uptake in Patients with Moderate Chronic Heart Failure: Relationship with Peak Oxygen Uptake and Prognosis.J Am Coll Cardiol 1999; 33: 759–766.
Yahara Y, Nomura Y, Okamoto S, Saitou K, Okamoto R, Makino K, et al. Assessment of Most Appropriate Background Subtraction Method for Quantification of123I-Metaiodobenzylguanidine (MIBG) Myocardial Uptake by Comparing with Plasma ANP and BNP.KAKU IGAKU (Jpn J Nucl Med) 2000; 37: 217–225. (in Japanese with English abstract)
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones Regulating Cardiovascular Function in Patients with Severe Congestive Heart Failure and Their Relation to Mortality.Circulation 1990; 82: 1730–1736.
Yoshikawa T, Handa S, Anzai T, Nishimura H, Baba A, Akashi M, et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure.Am Heart J 1996; 131: 329–336.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Imamura, Y., Fukuyama, T. Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy—Importance of background correction for quantification of MIBG activity. Ann Nucl Med 16, 387–393 (2002). https://doi.org/10.1007/BF02990076
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02990076